Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2018 | The evolution of MRD-guided therapy for leukemia

Richard Dillon, MBBS, from King’s College London, UK, discusses the current landscape for minimal residual disease (MRD) in acute myeloid leukemia (AML). The evolution of MRD-guided therapies is timely, with MRD moving to being clinically relevant. Dr Dillion mentions multiple studies conclusively proving that MRD is one of the most, if not the most, relevant prognostic factor in AML. In the last few years, MRD measurement has been incorporated into treatment protocols, enabling physicians to choose the best treatment for each individual patient. This interview was recorded at the British Society for Hematology (BSH) 2018 Annual Scientific Meeting, held in Liverpool, UK.